Clinical trial
Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes…
NCT00274300 · PowderMed, Industry · Completed
Key facts
| NCT number | NCT00274300 |
|---|---|
| Title | Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2 |
| Official title | A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate the Safety, Tolerability and Immunogenicity of pPJV7630, a Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused by HSV-2 |
| Lead sponsor | PowderMed, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HSV-2 |
| Intervention type | Biological |
| Interventions | pPJV7630 administered by PMED |
| Enrollment | 36 |
| Start date | Aug 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Jan 10, 2006 |
| Last update posted | Jan 29, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: